Reproductive Health Notes

Reproductive Health Notes

• Reproductive Health (WHO definition)

  • Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.

  • Reproductive health: people can have a satisfying and safe sex life, the capability to reproduce, and the freedom to decide if, when, and how often to do so.

Female Anatomy

• Reproductive system components

  • Internal: uterus, fallopian tubes, ovaries, cervix.

  • External: vulva (mons pubis, clitoris, labia majora, labia minora), vaginal opening, hymen, urethral opening.

• Key structures (listed in slides)

  • Fallopian tubes

  • Ovary

  • Uterus

  • Cervix

  • Vagina

  • Mons pubis

  • Clitoris

  • Urethral opening

  • Labia majora

  • Labia minora

  • Hymen

  • Vaginal opening

Embryology: Development of External Genitalia and Ducts

• Two distinct developmental processes: sex determination and sex differentiation.

• Sex determination

  • The undifferentiated zygote is steered toward a male or female trajectory at fertilization by a sperm contributing either an X or a Y chromosome.

  • External genitalia are undifferentiated in weeks 1–6 of gestation.

• Sex differentiation

  • Involves later development of gonads, ducts, and external genitalia.

• Gonad development timeline (overview)

  • Gonads begin as genital ridges without germ cells.

  • Week 4: germ cells migrate to genital ridges; reach by week 6.

  • Epithelium of genital ridges proliferates and penetrates intermediate mesoderm to form primitive sex cords, which later become testes or ovaries.

Embryology (Continued): Indifferent Gonads and Ducts

• At 4 weeks: indifferent gonads with Wolffian (mesonephric) ducts and Müllerian (paramesonephric) ducts present.

• Testis development (male):

  • Wolffian ducts develop into epididymis, vas deferens, seminal vesicles; Müllerian ducts regress.

• Ovarian development (female):

  • Müllerian ducts develop into fallopian tubes, uterus, cervix, and upper vagina; Wolffian ducts regress.

• Key anatomical illustration references (weeks):

  • 4 weeks: indifferent gonads with both ducts present.

  • 6 weeks: germ cells arrive; early testis cords or ovarian cortex form.

  • 8 weeks: differentiation into testicular cords or ovarian structures.

  • 16 weeks: transition toward ovarian or testicular structures continues.

  • 20 weeks: mature ovarian structures emerging (ovarian follicles).

• Clinical relevance: bicornuate uterus results from incomplete fusion of Müllerian ducts (two distinct uterine horns entering a single vagina).

Embryology (Continued): External Genitalia Development

• External genitalia begin forming in week 3.

• Cloacal folds form genital tubercle and urethral/anal folds; genital swellings develop on either side.

• Males

  • Genital tubercle → phallus (penis).

  • Urethral folds → urethra.

  • Genital swellings → scrotum.

• Females

  • Genital tubercle → clitoris.

  • Urethral folds and genital swellings → labia minora and labia majora.

  • Urogenital groove remains open to form the urethra and vagina.

Vulvar Anatomy

• Key regions shown on slides: clitoral hood, clitoris, mons pubis, labia majora, vestibule (urethral and vaginal openings), labia minora, forchette, posterior commissure, anus.

Uterine Anatomy

• The uterus is a secondary sex organ for maintenance and transport of gametes.

• Structure: thick-walled muscular organ capable of expansion for a growing fetus; connected distally to the vagina and laterally to the uterine tubes.

• Three parts: fundus, body, cervix.

• Normal orientation: anteverted and anteflexed.

  • Variants: excessively anteflexed; anteflexed and retroverted; retroflexed and retroverted (these variants do not inherently cause problems but may increase risk of uterine prolapse).

Uterine Tissue Layers and Endometrium

• Three layers: peritoneum (perimetrium), myometrium (thick smooth muscle), endometrium (inner mucosa).

• Endometrium has two key layers:

  • Stratum basalis: deepest layer, does not shed during menstruation.

  • Stratum functionalis: proliferates under estrogen, becomes secretory under progesterone, shed during menstruation, regenerates from basalis.

• Clinical relevance: Endometriosis – ectopic endometrial tissue outside the uterus; responds to estrogen, proliferates and bleeds, often causing dysmenorrhea and infertility.

Fallopian Tube Anatomy

• Primary function: transport ovum from ovary to uterus.

• Lining: inner mucosa with ciliated columnar epithelium and peg cells to move ovum toward uterus.

• Ampulla: widest section; fertilization usually occurs here.

• Clinical relevance: Salpingitis – inflammation of fallopian tubes, often from bacterial infection; adhesions can block lumen, leading to infertility or ectopic pregnancy.

Ovarian Anatomy

• Main functions: produce oocytes and sex steroids (estrogen and progesterone) in response to LH and FSH.

• Histology: three main features

  • Surface epithelium (germinal epithelium).

  • Cortex: connective tissue stroma with numerous follicles (each follicle contains an oocyte).

  • Medulla: loose connective tissue with rich neurovascular networks.

Important Definitions

• Thelarche: development of breast tissue.

• Pubarche: development of axillary and pubic hair.

• Menarche: first menstrual period.

• Puberty: age at which reproduction becomes possible via endocrine and gametogenic function of gonads.

The Menstrual Cycle: Overview

• Average cycle length: $28 ext{ days}$.

• Normal range: $23-35 ext{ days}$.

• Four control mechanisms:

  • Hypothalamus

  • Pituitary gland

  • Ovaries

  • Endometrium

• Temporal pattern relates to follicular development, ovulation, and endometrial changes.

The Menstrual Cycle: Timeline and Hormones

• Cycle phases: follicular (proliferative), ovulation, luteal (secretory); menstruation marks start of new cycle.

• Typical days: 0 (start of menstruation) to ~28 (end of cycle) with day 14 often around ovulation in a 28-day cycle.

• Hormones involved: FSH, LH, estrogen (estradiol), progesterone.

• Diagram reference: cycle days chart showing rise and fall of hormones across the cycle.

Phase 1: The Follicular/Proliferative Phase

• Timing: day 1 to day 14 in a 28-day cycle (variability due to follicular length).

• Hormone dominance: estrogen predominates, mainly $ext{17}\beta- ext{estradiol}$.

• Mechanism: increased estrogen results from upregulation of FSH receptors in the growing follicle.

• Purpose: endometrium grows and proliferates to prepare for potential pregnancy.

Follicular Phase (Continued)

• End of phase: rising estradiol provides negative feedback to the anterior pituitary.

• Functional purpose: to create a receptive endometrium for potential sperm.

Ovulation

• Timing: occurs about 14 days before menses in a 28-day cycle (commonly day 14).

• Trigger: high estradiol levels produce a positive feedback on FSH and LH, causing the LH surge.

• Event: mature follicle ruptures and releases an oocyte.

• Post-ovulation: estradiol levels fall at the end of ovulation.

Phase 2: The Luteal/Secretory Phase

• Timing: day 14 to day 24 of a 28-day cycle.

• Hormone dominance: progesterone becomes the dominant hormone (stimulated by LH) and supports endometrium.

• End of phase: corpus luteum forms at the site of the mature follicle rupture and secretes estradiol and progesterone.

• Endometrial preparation: increased vascular supply and secretions to support potential pregnancy.

Corpus Luteum and Corpus Albicans

• Corpus luteum forms from the ruptured follicle and secretes progesterone and estrogen.

• If pregnancy does not occur, it regresses to become corpus albicans.

• Follicle development stages labeled: primary follicle, secondary follicle, vesicular (graafian) follicle, ovulation, corpus luteum, corpus albicans.

Uterus Lining Across the Cycle

• Menstrual cycle phases mapped to endometrium: menstrual, proliferative (follicular), secretory (luteal).

• Key phases visualization: days 1-5 menstruation; days 6-14 proliferative; day 14 ovulation; days 15-28 secretory.

Menstruation

• Definition: shedding of the endometrium due to a drop in hormone levels.

• Cycle day: considered days 0-5 of the next cycle (start of menses).

• Blood characteristics: menstrual blood is ~75% arterial; contains tissue debris, prostaglandins, and endometrial tissue.

• Volume: typical loss is ~30 mL; range can be up to 80 mL; >80 mL considered abnormal.

Anovulatory Cycles

• Definition: cycles in which ovulation does not occur.

• Typical in: first two years after menarche and before menopause.

• Consequences: no corpus luteum; progesterone effect on endometrium is absent.

• Endometrium continues to grow under estrogen and may slough off irregularly; cycle length generally < or around 28 days; variable flow.

Amenorrhea

• Primary amenorrhea: failure to reach menarche.

• Evaluation criteria: no secondary sex characteristics by age 13; no menarche by 5 years after breast development; or by age 15 regardless of development.

• Etiology (major categories): anatomical defects, elevated FSH, hyperprolactinemia, hypothalamic amenorrhea, PCOS, gonadal dysgenesis (Turner syndrome contributes ~43% of cases).

Anatomical Defects and Related Etiologies

• Müllerian agenesis: uterus and vagina absent with otherwise normal external female characteristics (10% of primary amenorrhea).

• Imperforate hymen or transverse vaginal septum: partial/complete vaginal obstruction.

• Hyperprolactinemia: prolactin inhibits GnRH, reducing pituitary gonadotropins and gonadal function.

Polycystic Ovarian Syndrome (PCOS)

• Most common cause of amenorrhea with androgen excess.

• Triad: hyperandrogenism, polycystic ovaries, ovulatory dysfunction.

• Epidemiology: incidence < 1% in the U.S. (context within primary amenorrhea).

Pathophysiology of Amenorrhea (General)

• Four components required for normal menstrual function: genital outflow tract, ovaries, pituitary, hypothalamus.

• If any component is non-functional, bleeding cannot occur.

Assessment and Evaluation (Amenorrhea)

• Thorough history and physical exam; rule out pregnancy.

• Inquire about pubertal development and cyclic abdominal pain; assess for imperforate hymen or septum.

• Review medications; consider galactorrhea, headaches, or visual changes (pituitary issues).

• Medication and history screening: weight loss, etc.

Treatment/Management (Amenorrhea)

• Treat underlying cause.

• Imperforate hymen: surgical opening (cruciate incision).

• Transverse septum: surgical removal.

• Cervical hypoplasia: rarely repaired surgically; hysterectomy may be considered in severe cases; preserve ovaries for fertility via IVF/gestational carrier if desired.

• Gonadal failure/hypogonadotropic hypogonadism: cyclic estrogen and progestin therapy to initiate/mature/maintain secondary sexual characteristics.

• For females with short stature: avoid high-dose estrogen (risk of premature epiphyseal closure).

• For pituitary tumors: resection or medical therapy (e.g., dopamine agonists like cabergoline for prolactinomas).

Secondary Amenorrhea

• Definition: menstruation ceases for ≥6 months in a patient who has previously menstruated (some sources use ≥3 months).

• General causes fall into three categories:

  • Hormonal disturbances

  • Physical damage to the endometrium

  • Obstruction of the outflow tract of menstrual blood

Pathophysiology and Common Causes of Secondary Amenorrhea

• Most common cause: pregnancy.

• Hormonal causes include: pregnancy, lactation, thyroid dysfunction, hyperprolactinemia, hyperandrogenism (PCOS), suppression by OCPs.

• Structural causes: Asherman syndrome (intrauterine adhesions), cervical stenosis, endometrial damage.

Assessment (Secondary Amenorrhea)

• Comprehensive menstrual history.

• Determine birth control method and inciting events (surgery, pregnancy, trauma, D&C).

• Assess symptoms: headaches/vision changes, galactorrhea, thyroid symptoms, hirsutism, acne (suggest PCOS).

• Consider stress or excessive exercise as contributing factors; evaluate for hypogonadotropic hypogonadism.

Treatment/Management (Secondary Amenorrhea)

• Treat underlying cause.

• PCOS: weight loss, metformin for insulin resistance, OCPs for cycle control.

• Hypothyroidism: thyroxine replacement.

• Hyperthyroidism: thioamides, ablation, or surgery.

• Hyperprolactinemia: bromocriptine, cabergoline, or surgical excision.

• Asherman syndrome: hysteroscopic lysis of adhesions.

• Cervical stenosis: cervical dilation.

Dysmenorrhea

• Definition: pain with menses.

• Types: Primary and Secondary.

Primary Dysmenorrhea

• Definition: cramping pain beginning shortly before or at menses without pelvic pathology.

• Epidemiology: common in young females; 6–24 months after menarche.

• Prevalence: 45–95% of women of reproductive age; 2–29% experience severe pain; most affected are <24 years.

• Pathophysiology: not fully clear; increased prostaglandin secretion, especially during the late luteal phase in regular cycles; higher prostaglandins in dysmenorrhea patients on endometrial biopsy.

• Treatment

  • NSAIDs (prostaglandin synthesis inhibition).

  • Hormonal contraceptives (suppress ovulation and endometrial proliferation, reducing prostaglandin production).

  • Acetaminophen.

  • Nonpharmacologic: heat, exercise.

  • Surgical interventions (less evidence): laparoscopic uterosacral nerve ablation, presacral neurectomy, hysterectomy (hysterectomy reserved as last resort).

Secondary Dysmenorrhea

• Associated with identifiable pelvic pathology/internal pathology or uterine disease.

• Common causes: endometriosis, uterine fibroids (leiomyomas), adenomyosis, endometrial polyps, PID, possibly intrauterine contraceptive device (IUD).

Common Findings in Dysmenorrhea

• Young age favors primary dysmenorrhea; older age (>25) suggests secondary.

• PID signs: vaginal discharge, foul odor, or gray/white discharge; dysuria, dyspareunia, dyschezia, infertility.

• Uterine findings: enlarged, symmetric uterus with adenomyosis; enlarged, asymmetric uterus with fibroids.

• Pelvic masses may indicate fibroids, neoplasms, or ovarian cysts.

Evaluation of Dysmenorrhea

• History and physical examination.

• Pelvic exam; ultrasound; STI testing.

• Laparoscopy: may be indicated if noninvasive tests fail to identify cause.

Menopause

• Definition: routine, non-pathologic cessation of menses for ≥12 months.

• Median age: ~$51$ years.

Etiology and Epidemiology of Menopause

• Ovarian follicles diminish; granulosa cells decline, reducing estrogen and inhibin.

• Loss of negative feedback increases FSH/LH; estrogen declines, HPO axis disrupted; periods become irregular, then stop.

• Post-hysterectomy with bilateral oophorectomy can precipitate menopause.

• Epidemiology: about 1.3 million women become menopausal each year; typical age range 51–52; ~5% experience early menopause 40–45; ~1% before 40.

Pathophysiology of Menopause

• Normal aging process with rapid decline in primary ovarian follicles; insufficient response to FSH; no LH surge; no ovulation.

Evaluation of Menopause

• History and physical examination.

• Vasomotor symptoms: ~75% experience hot flashes, night sweats, palpitations, migraines.

• Urogenital symptoms: ~60% experience vaginal/urethral atrophy and sexual dysfunction.

• Psychogenic symptoms: ~45% experience irritability, anxiety, depression, sleep disturbances, concentration issues, low self-esteem.

Management of Menopause

• Hormonal therapy (estrogen-containing) can alleviate vasomotor symptoms and prevent vaginal atrophy.

  • Use the lowest effective dose for the shortest duration.

  • Consider risks: increased relative risk of breast and ovarian cancer, thromboembolism, stroke, and coronary heart disease; higher breast cancer risk after 3–5 years.

• Non-Hormonal options: SSRIs, SNRIs, gabapentin, clonidine; useful for vasomotor symptoms; can be used short-term.

• Non-prescription approaches: dietary changes (vitamin E, omega-3 fatty acids).

• Individualized risk-benefit assessment required for hormone therapy.

*** End of Notes ***